These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32832636)

  • 21. Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration.
    Guha R; Yue B; Dong J; Banerjee A; Serrero G
    Breast Cancer Res Treat; 2021 Apr; 186(3):637-653. PubMed ID: 33616772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
    Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
    Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.
    Barbie TU; Alexe G; Aref AR; Li S; Zhu Z; Zhang X; Imamura Y; Thai TC; Huang Y; Bowden M; Herndon J; Cohoon TJ; Fleming T; Tamayo P; Mesirov JP; Ogino S; Wong KK; Ellis MJ; Hahn WC; Barbie DA; Gillanders WE
    J Clin Invest; 2014 Dec; 124(12):5411-23. PubMed ID: 25365225
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
    Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
    Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
    Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
    Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NOTCH4 is a potential therapeutic target for triple-negative breast cancer.
    Nagamatsu I; Onishi H; Matsushita S; Kubo M; Kai M; Imaizumi A; Nakano K; Hattori M; Oda Y; Tanaka M; Katano M
    Anticancer Res; 2014 Jan; 34(1):69-80. PubMed ID: 24403446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
    Morry J; Ngamcherdtrakul W; Gu S; Reda M; Castro DJ; Sangvanich T; Gray JW; Yantasee W
    Mol Cancer Ther; 2017 Apr; 16(4):763-772. PubMed ID: 28138033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple suppressing small interfering RNA for cancer treatment-Application to triple-negative breast cancer.
    Lee J; Bang JH; Ryu YC; Hwang BH
    Biotechnol J; 2023 Nov; 18(11):e2300060. PubMed ID: 37478121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor Effect of Demethylzeylasteral (T-96) on Triple-Negative Breast Cancer via LSD1-Mediate Epigenetic Mechanisms.
    Shen Z; Gu Y; Jiang R; Qian H; Li S; Xu L; Gu W; Zuo Y
    Anal Cell Pathol (Amst); 2022; 2022():2522597. PubMed ID: 36276611
    [No Abstract]   [Full Text] [Related]  

  • 34. Silencing of Pyruvate Kinase M2
    Huang S; Zhu W; Zhang F; Chen G; Kou X; Yang X; Ouyang G; Shen J
    ACS Appl Mater Interfaces; 2021 Dec; 13(48):56972-56987. PubMed ID: 34797638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
    Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
    Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
    [No Abstract]   [Full Text] [Related]  

  • 36. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
    Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
    Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.
    Su S; Tian Y; Li Y; Ding Y; Ji T; Wu M; Wu Y; Nie G
    ACS Nano; 2015 Feb; 9(2):1367-78. PubMed ID: 25611071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer.
    Li S; Wei Q; Li Q; Zhang B; Xiao Q
    Cancer Biol Ther; 2015; 16(6):866-75. PubMed ID: 25920936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.